Sign In
Buy CLSD
$0.410
+0 (+0%)
At Close: Mar 13, 2026
3 Cheap Stocks to Buy Under $1 in October 2023
12:24am, Thursday, 26'th Oct 2023
For the extreme gambler who has done homework regarding risk and rewards, few thrills excite as much as cheap stocks to buy under $1. By logical deduction, of course, we're talking about penny stocks.
Clearside Biomedical to Participate in Panel Discussion at the Cantor Global Healthcare Conference
07:05am, Tuesday, 19'th Sep 2023
ALPHARETTA, Ga., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the
Clearside Biomedical to Participate in Upcoming Investor Conferences in August 2023
04:30pm, Wednesday, 02'nd Aug 2023
ALPHARETTA, Ga., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the
Clearside Biomedical to Report Second Quarter 2023 Financial Results and Provide Corporate Update on Monday, August 14, 2023
07:05am, Tuesday, 01'st Aug 2023
ALPHARETTA, Ga., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the
Clearside Biomedical CEO George Lasezkay to Present at the SHARE™️ Series Investor Event on Monday, July 17, 2023
04:05pm, Tuesday, 11'th Jul 2023
ALPHARETTA, Ga., July 11, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the
Clearside Biomedical, Inc. (CLSD) Reports Q1 Loss, Misses Revenue Estimates
09:56am, Thursday, 11'th May 2023
Clearside Biomedical, Inc. (CLSD) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to loss of $0.13 per share a year ago.
Clearside Biomedical to Report First Quarter 2023 Financial Results and Provide Corporate Update on Thursday, May 11, 2023
07:05am, Tuesday, 02'nd May 2023
ALPHARETTA, Ga., May 02, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the s
Clearside Biomedical, Inc. (CLSD) Q4 2022 Earnings Call Transcript
08:22pm, Thursday, 09'th Mar 2023
Clearside Biomedical, Inc. (NASDAQ:CLSD ) Q4 2022 Earnings Conference Call March 9, 2023 4:30 PM ET Company Participants Jenny Kobin - Investor Relations George Lasezkay - President and Chief Executiv
Clearside Biomedical, Inc. (CLSD) Reports Q4 Loss, Tops Revenue Estimates
07:49pm, Thursday, 09'th Mar 2023
Clearside Biomedical, Inc. (CLSD) delivered earnings and revenue surprises of -23.08% and 111.54%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for t
ALPHARETTA, Ga., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the
Clearside Biomedical, Inc. (CLSD) Q3 2022 Earnings Call Transcript
04:41pm, Wednesday, 09'th Nov 2022
Clearside Biomedical, Inc. (NASDAQ:CLSD ) Q3 2022 Earnings Call Transcript November 9, 2022 8:30 AM ET Company Representatives George Lasezkay - Chief Executive Officer Tom Ciulla - Chief Medical Offi
Webcast and Conference Call on Wednesday, November 9, 2022 at 8:30 A.M. ET Hosted by Management and Including Key Opinion Leader, Arshad Khanani, M.D. Webcast and Conference Call on Wednesday, Novembe
Clearside Biomedical to Report Third Quarter 2022 Financial Results and Provide Corporate Update on Wednesday, November 9, 2022
07:05am, Wednesday, 02'nd Nov 2022
ALPHARETTA, Ga., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the s
CLS-AX Wet AMD Clinical Trial Data from OASIS Cohorts 3 & 4 Expected in November 2022 CLS-AX Wet AMD Clinical Trial Data from OASIS Cohorts 3 & 4 Expected in November 2022
Clearside Biomedical to Present at the Ophthalmology Futures Retina Forum 2022
07:05am, Thursday, 25'th Aug 2022
ALPHARETTA, Ga., Aug. 25, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the s
